Butylphthalide.
A celery seed compound that relaxes blood vessel walls in laboratory preparations. In several countries it is a prescription medicine rather than a supplement ingredient.
- Category
- Compound
What Butylphthalide is, and what it does.
- Does it work
- This one belongs with clinicians and the people they look after. If the celery angle interests you, celery seed oil is the food-form relative you'll find on a shelf.
- How much to take
- No dose figure is on record. Where it is a prescription medicine, the amount is set by a prescriber rather than by a label.
- Time to feel it
- Nobody has measured a time to effect for it outside supervised clinical use.
- The first dose
- Day one has nothing you'd sense. The capsule is oil filled, so it's absorbed along with the fat in a meal.
- With regular use
- Use over weeks outside a prescribing setting has not been characterised, so there is no honest week-by-week picture to give.
- How well tolerated
- It is handled by liver CYP enzymes, so other medicines can shift exposure either way. Because it is prescription-only in some countries, speak to a doctor or pharmacist first.
- How it feels
- No subjective reports have been published from supplement-style use. Celery-derived oils taste and smell strongly of celery.
- The overlooked benefit
- The same phthalide family gives celery its smell, and celery seed oil on a supplement shelf is the food-form cousin of the laboratory-made version.
The proof, claim by claim.
These words describe the research, not the molecule's worth. Research strength is how much work stands behind one claim, and it is never a product score.
- relaxation of vascular smooth muscleIn vitro study
- microcirculatory blood flowAnimal study
- mitochondrial function in nerve tissueAnimal study
- hepatic CYP-mediated metabolism and exposureNarrative review
Why these belong in the same formula. Each row says what the basis is, from settled biochemistry through to a trial that measured the pair.
Li and colleagues found that disrupting the intestinal microbiota with antibiotics changed measured butylphthalide exposure in vivo. That implicates microbial metabolism or microbially influenced absorption in how much of a dose is available. Anything that reshapes the gut community, including antibiotics and probiotic use, is therefore a plausible source of variability.
The compound is formulated in soft capsules dissolved in vegetable oil because it will not dissolve in water. A defined medium chain triglyceride vehicle gives more consistent dispersion than relying on stomach contents. This affects exposure, not intrinsic activity.
Butylphthalide has been described as reducing platelet aggregation in laboratory work, and high dose EPA and DHA do the same through eicosanoid substrate competition. Stacking them adds bleeding risk, particularly alongside prescribed antiplatelet medicines. This pairing belongs on a caution list.
Ginkgo terpene lactones antagonise platelet activating factor and butylphthalide has its own reported antiplatelet activity. The combination is popular in the same product category, which is exactly why the overlap deserves flagging. There is no controlled human work on the pair.
The metabolic work by Lu and colleagues points toward mitochondrial and energy metabolism effects in a rodent model. Coenzyme Q10 sits directly in the electron transport chain. The overlap is mechanistic and animal derived, so read it as a hypothesis rather than as a clinical pairing.
Ligustilide and butylphthalide belong to the same phthalide family and share structural features. Traditional Angelica preparations therefore supply chemically related molecules from a different plant source. Structural relatedness is not the same as equivalent activity, and the two should not be dose compared.
Nothing specific on file for Butylphthalide. Match the label to the daily amount above, and tell your doctor what you take.
Not medical advice. Show the label to your pharmacist.What Butylphthalide actually does.
This compound was first found in celery seed oil, but the version used as a medicine is a lab made synthetic form.
It barely dissolves in water, which is why it comes in oil filled soft capsules instead of a dry powder.
In some countries this is a prescription medicine, not a regular supplement ingredient, so it sits outside normal self directed use.
Your liver breaks this down using enzymes that many other drugs also use, so taking it alongside strong inhibitors or inducers of those enzymes can change how much of it stays in your system.
Where Butylphthalide comes from.
This compound was first found in celery seed oil, but the version used in studies is made in a lab. It does not dissolve in water, so it comes in oil filled capsules. In several countries it is a prescription drug, not something to pick up off a supplement shelf.
The same molecule is reached more than one way. Which route a given product used is a manufacturing choice, and the finished compound is the same either way.
The natural L isomer occurs in Apium graveolens seed oil, while commercial material is built synthetically from phthalide precursors
A butyl group is introduced at the 3 position to give racemic 3 n butylphthalide
The oily product is purified and residual solvents removed to pharmaceutical specification
Lots are specified for purity and, where relevant, for the DL ratio
Dissolved in vegetable oil and encapsulated, or emulsified for infusion
Getting Butylphthalide from food.
The whole-food sources on file. A supplement closes the gap, it does not replace dinner.
A gram-for-gram figure (how much of each you would eat to match a dose) will appear here once it is sourced and reviewed. This page will not print a number it cannot cite.
The forms it comes in.
The essence, in one line each.
- The authors report region specific metabolic changes with DL 3 n butylphthalide in their spatial metabolomics analysis of a cerebral ischemia reperfusion model.Animal study. Lu et al., 2025 (Neurotherapeutics). PMID 39880748 β
- The authors report that antibiotic disruption of the intestinal microbiota altered the pharmacokinetic profile of n butylphthalide in vivo.Animal study. Li et al., 2024 (PLoS One). PMID 38917098 β
- The authors compare neuroprotective agents on neurological function and prognosis measures and place butylphthalide among the agents assessed.Systematic review. Wang et al., 2024 (Frontiers in Neuroscience). PMID 39834702 β
These are the studies our verdict leans on, chosen from the 3 we read for Butylphthalide. The full linked list is below.
The studies, linked.
12 sources behind our Butylphthalide verdict: peer-reviewed studies and registered clinical trials. Every one links straight to PubMed, the journal, or ClinicalTrials.gov. Read them yourself.
- Clinical trialEfficacy and Safety of Butylphthalide for Acute Ischemic Stroke Patients Receiving Intravenous Thrombolysis or Endovascular Treatment: A Prospective, Randomized, Double-blinded, Placebo Parallel Controlled, Multiple-center Trial.ClinicalTrials.gov βPhase 3, 1,216 participants, Completed
- Clinical trialEffect of Early Initiation of Butylphthalide on Neural Function in Patients With Acute Ischemic Stroke -A Prospective, Multicenter, Randomized, Open-label, Blinded End TrialClinicalTrials.gov βPhase 2, 204 participants, Completed
- Clinical trialEffect of Butyphthalide on Cognitive Level Change After Cerebral Vascular Event-a Randomized Control Trial (Be-CLEVER)ClinicalTrials.gov βPhase 3, 3,200 participants, Recruiting
- Clinical trialIsosorbide Mononitrate and Butylphthalide to Reduce the Risk of Disability in Patients With Acute Lacunar Stroke: a 2Γ2 Factorial Randomized Controlled Trial (IMPACT)ClinicalTrials.gov βPhase 3, 3,156 participants, Not yet recruiting
- Clinical trialA Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Long-Term Efficacy of Butylphthalide in Patients With Minor Acute Ischemic Stroke (BLESS)ClinicalTrials.gov βPhase 3, 1,200 participants, Not yet recruiting
- Clinical trialThe Effectiveness and Safety of Butylphthalide Soft Capsules in Secondary Prevention of Ischemic Stroke TrialClinicalTrials.gov βPhase 4, 1,000 participants, Unknown
- Clinical trialA Multi-center, Random, Double Blind and Placebo Control Phase III Clinical Study on the Efficacy and Safety of Butylphthalide Soft Capsule for the Treatment of Vascular DementiaClinicalTrials.gov βPhase 3, 707 participants, Active not recruiting
- Clinical trialStudy of Collateral Circulation and Related Gene Polymorphism in Patients With Symptomatic Intracranial Anterior Circulation Aortic OcclusionClinicalTrials.gov βPhase 4, 500 participants, Unknown
- Clinical trialA Multi-center, Randomized, Single-blind, Placebo-controlled Study of Dl-3-n-butylphthalide in Patients With Moyamoya Disease of High Risk for Ischemic Cerebrovascular Events After Extracranial-to-intracranial Revascularization SurgeryClinicalTrials.gov βPhase 3, 450 participants, Unknown
- Clinical trialNeuroprotective Effect of Butylphthalide Injection on Patients With Return of Spontaneous Circulation After Cardiac ArrestοΌa Multicenter, Randomized Clinical TrialClinicalTrials.gov βPhase 4, 350 participants, Recruiting
- Clinical trialSafety and Efficacy of Butylphthalide Soft Capsules for Cognitive Impairment Comorbid With Focal Epilepsy in Elderly Patients: A Multicenter, Randomized, Double-Blind, Placebo-Controlled TrialClinicalTrials.gov βPhase 4, 220 participants, Recruiting
- Clinical trialThe Efficacy of Butylphthalide Soft Capsules in Patents With VCIND:A Randomized, Double-blind,and Neuroimaging StudyClinicalTrials.gov βPhase 2, 200 participants, Unknown
Evidence surfaced via Semantic Scholar (Allen Institute for AI) and ClinicalTrials.gov. Ranked by study type and citation weight, not cherry-picked.
Problems people have reported.
Read this carefully. These are 266 voluntary, unverified reactions reported to the FDA (openFDA). The number mostly reflects how popular Butylphthalide is, not how risky it is. A report is not proof Butylphthalide caused anything. It is a signal of what to watch for, nothing more.
Source: openFDA adverse-event reports. Voluntary reporting, not an incidence rate.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.